Company Overview of Aelin Therapeutics NV
Aelin Therapeutics NV develops antibiotics and therapeutics using the Pept-in technology. The company's technology platform harnesses protein aggregation to induce functional knockdown of a target protein. The company's products have applications against Methicillin-resistant Staphylococcus aureus (MRSA) and undruggable targets in humans. The company was founded in 2017 and is headquartered in Heverlee, Belgium.
Gaston Geenslaan 1
Founded in 2017
Key Executives for Aelin Therapeutics NV
Aelin Therapeutics NV does not have any Key Executives recorded.
Aelin Therapeutics NV Key Developments
Similar Private Companies By Industry
|ADx NeuroSciences NV||Europe|
|Aelin Therapeutics NV||Europe|
|Apitope International NV||Europe|
Recent Private Companies Transactions
December 11, 2017
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Aelin Therapeutics NV, please visit aelintherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.